Systems and Methods for Buffered Aerosol Drug Delivery

• US 20190328040A1
• Filed: 04/26/2019
• Published: 10/31/2019
• Est. Priority Date: 04/30/2018
• Status: Abandoned Application

• Current Assignee: Zayd Abdulfuhah Turbi
• Original Assignee: Zayd Abdulfuhah Turbi
• Inventors: Turbi, Zayd Abdulfuhah
• Application Number:
  US16/396,459
• Publication Number:
  US 20190328040A1
• Time in Patent Office: Days
• CPC Class Codes: A24B 15/167 in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
• CPC Class Codes: A24F 40/10 Devices using liquid inhalable precursors
• CPC Class Codes: A24F 40/40 Constructional details, e.g. connection of cartridges and battery parts
• CPC Class Codes: A61K 31/352 condensed with carbocyclic rings, e.g. methantheline cannabinoids A61K31/658
• CPC Class Codes: A61K 9/007 Pulmonary tract; Aromatherapy
• CPC Class Codes: A61K 9/12 Aerosols; Foams A61K9/0043, A61K9/0056, A61K9/006, A61K9/0073 take precedence; spray-films A61K9/7015
• CPC Class Codes: A61M 11/042 electrical
• CPC Class Codes: A61M 15/06 Inhaling appliances shaped like cigars, cigarettes or pipes
• CPC Class Codes: A61M 2016/0021 with a proportional output signal, e.g. from a thermistor
• CPC Class Codes: A61M 2016/0027 pressure meter
• CPC Class Codes: A61M 2016/0033 electrical
• CPC Class Codes: A61M 2202/04 Liquids
• CPC Class Codes: A61M 2202/06 Solids
• CPC Class Codes: A61M 2205/0216 Materials providing elastic properties, e.g. for facilitating deformation and avoid breaking
• CPC Class Codes: A61M 2205/123 with incorporated reservoirs
• CPC Class Codes: A61M 2205/332 Force measuring means
• CPC Class Codes: A61M 2205/3331 Pressure; Flow
• CPC Class Codes: A61M 2205/3368 Temperature
• CPC Class Codes: A61M 2205/3576 with non implanted data transmission devices, e.g. using external transmitter or receiver
• CPC Class Codes: A61M 2205/52 with memories providing a history of measured variating parameters of apparatus or patient
• CPC Class Codes: A61M 2205/583 : by visual feedback
• CPC Class Codes: A61M 2205/8206 : battery-operated

Abstract

A method for delivering a drug to a user including an electronic cigarette wherein the electronic cigarette itself includes a liquid formulation. The liquid formulation can include at least one drug and at least one biologically acceptable carrier. The at least one drug can be formed with an acid or alcohol and has a first vapor pressure at a first temperature, and is heated by a heating element within the electronic cigarette resulting in the generation of an aerosol suitable for inhaling by the user. Often, the drug can include nicotine, but may also be configured to include cannabinol or can be associated with nicotine replacement therapies, or other medication-assisted therapies. The drugs may also have a salt or co-salt added in order to increase the effectiveness of drug delivery while lowering the need for a higher powered heating element.

Claims

1. A method for delivering a drug to a user comprising:

an electronic cigarette wherein the electronic cigarette comprises a liquid formulation comprising;

at least one drug; and

at least one biologically acceptable carrier;

wherein the at least one drug is formed with an acid or alcohol and has a first vapor pressure at a first temperature; and

wherein the liquid formulation is heated by a heating element resulting in the generation of an aerosol suitable for inhaling by the user.

2. The method of claim 1, wherein the at least one drug is nicotine.

3. The method of claim 1, wherein the at least one drug is cannabinol.

4. The method of claim 1, wherein the at least one drug is associated with a nicotine replacement therapy.

5. The method of claim 1, wherein the at least one drug is associated with a medication-assisted therapy.

6. The method of claim 1, wherein the at least one drug is salt-based.

7. The method of claim 1, wherein the first vapor pressure is less than 20 millimeters of mercury (mmHg).

8. The method of claim 1, wherein the first temperature is approximately 200 degrees Celsius.

9. The method of claim 1, wherein the at least first drug further comprises a first melting point and a first boiling point and wherein the difference between the first melting point and the first boiling point is at least 50 degrees Celsius.

10. The method of claim 9, wherein the heating element operates at a first operating temperature and the first boiling point of the first drug is less than 40 degrees Celsius lower than the operating temperature.

11. A liquid storage device comprising:

a housing suitable for coupling with an electronic cigarette wherein the coupling provider thermal communication with a heating element within the electronic cigarette;

a liquid formulation comprising;

at least one drug; and

at least one biologically acceptable carrier;

wherein the at least one drug is formed with an acid or alcohol and has a first vapor pressure at a first temperature; and

wherein the liquid formulation is heated by the heating element resulting in the generation of an aerosol suitable for inhaling by a user.

12. The device of claim 11, wherein the at least one drug is nicotine.

13. The device of claim 11, wherein the at least one drug is cannabinol.

14. The device of claim 11, wherein the at least one drug is associated with a nicotine replacement therapy.

15. The device of claim 11, wherein the at least one drug is associated with a medication-assisted therapy.

16. The device of claim 11, wherein the at least one drug is salt-based.

17. The device of claim 11, wherein the first vapor pressure is less than 20 millimeters of mercury (mmHg).

18. The device of claim 11, wherein the first temperature is approximately 200 degrees Celsius.

19. The device of claim 11, wherein the at least first drug further comprises a first melting point and a first boiling point and wherein the difference between the first melting point and the first boiling point is at least 50 degrees Celsius.

20. The device of claim 19, wherein the heating element operates at a first operating temperature and the first boiling point of the first drug is less than 40 degrees Celsius lower than the operating temperature.